|Headquarters||New Delhi, India|
|Key people||Soshil Kumar (Executive Chairman of the Board, Ravinder Jain (Managing Director), Dr. Rajesh Jain (Joint Managing Director), Sandeep Jain (Joint Managing Director)|
|Products||Pharmaceuticals, generic drugs, vaccine|
Panacea Drugs Pvt. Ltd. was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. Panacea Biotec is an Indian research based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products. It is one of the three largest biotech companies in India. In August 2011 several of its hepatitis vaccines were removed from the list of prequalified vaccines by the World Health Organization because of quality management issues, but the issues were resolved by early 2012.
Panacea Biotec has 5 research centres across India that specialize in the fields of pharmaceuticals, biotechnology, natural products and biopharmaceutics.
Panacea Biotec is the largest Vaccine manufacturing Company in India and is well acknowledged by the UN Health Agencies in partnering the Polio eradication initiative with supplies of millions of doses of WHO Pre-qualified Polio vaccine. As a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV) Panacea Biotec has introduced the next generation Inactivated Polio vaccine (eIPV) vide a collaboration with the Netherland Vaccine Institute. This vaccine has found extensive usage in India for more than 3 years now and is registered in Bangladesh. IPV is also in advanced stage of registration in 10 countries word wide with the target of being in more than 30 countries in a couple of years and has been put up for WHO prequalification which is expected soon.
Panacea Biotec timeline:
- 1984-Panacea Drug (P) Ltd. was formed
- 1988-Established a plant for vaccines production at New Delhi, under the name of Radicura Pharma
- 1989-Pharmaceutical formulations plant at New Delhi,under the name of Panacea Drug P Ltd.
- 1993-Merger of Panacea Drugs (P) Ltd. & Radicura Pharma to form Panacea Biotec Ltd.
- 1995-IPO of Equity Shares of Rs.180 Million
- 1995-State -of the- art Drug Delivery R&D centre at Lalru
- 1997-First Product Patent in Several Countries
- 2001-R&D tie up with European MNC
- 2002-In-licensing Agreement with Biotechnology Consortium of India for Development & Commercialization of Anthrax Vaccine
- 2002-Commissioning of Recombinant Vaccine Production Plant
- 2004-In-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine
- 2004-Marketing Joint Venture with Chiron (now Novartis) Vaccines, UK
- 2004-Collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines
- 2005-In-licensing agreement with National Institute of Health, USA for Hair Growth Hormone
- 2006-WHO cGMP complaint ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh.
Landmark collaborations with The Netherlands Vaccine Institute (The Nederlands Vaccin Instituut (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration with PT.Bio Farma to manufacture & market Measles Vaccine. Inauguration of Biopharmaceutical R&D Centre at New Delhi Pre-Qualification Certification from WHO for Supply of Recombinant Hepatitis-B Vaccine to UN Agencies. Collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine.
- 2007-Vaccine Formulation Plant at Baddi
Research Agreement with Punjab University to develop New Chemical Entities for Psychiatric Disorders
- 2008-Foray into Healthcare Delivery –collaboration to set-up 220 bed multi super-specialty hospital in NCR
WHO prequalification for fully liquid innovative combination Pentavalent vaccine, EasyFive* against five deadly infectious diseases (DTwP+ Hep B+ Hib) of early childhood. Granted a patent from US Patent & Trademark Office for our product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles (Patent No. 7,371,412 B2)
Panacea Biotec - Kremers Urban Inc. Allianc
Panacea Biotec enjoys a rich tradition of collaborations and joint ventures with various industry players and business relationships with national & international research institutes, academic universities and commercial corporations for the purpose of securing in-licensing, out sourcing and other business opportunities and to develop strong product portfolio. Panacea Biotec - Kremers Urban Inc. Alliance Panacea Biotec, India's highly progressive research based health management company has entered into a strategic alliance with Kremers Urban Inc. (part of UCB Group) for 11 high barrier to entry generics, whose market size in US at the innovator level is around USD 4 billion. The first product in this portfolio to reach the market is Tacrolimus Capsules that is being launched in US in Nov 2012. Panacea Biotec was granted approval of the product from the United States Food and Drug Administration (FDA) in September 2012. Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received organ transplants. Tacrolimus is in a class of medications called immunosuppressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. The total market size of Tacrolimus is approximately USD 892 million in US. Currently there are 5 generic players in US; namely Sandoz, Dr Reddy’s, Mylan, Watson and Accord Healthcare. The innovator brand Prograf® accounts for approximately 43% of Tacrolimus sales in terms of units sold and generics account for the remaining 57%.
Panacea Biotec-Osmotica Alliance
Panacea NewRise Hospital, Gurgaon
Nederlands Vaccine Institute (NVI), Netherlands
National Research Development Corporation (NRDC), India
PT Bio Farma, Indonesia
National Institute of Health, USA
National Institute of Immunology, India
Biotech Consortium India Ltd
Panacea Biotec's portfolio consists of many key brands across the various therapeutic segments.Panacea Biotec has engineered its sales and marketing network for pharmaceutical formulations into strategic business units (SBUs), which comprise Critical Care, Diacar, Procare and Growcare. The company has launched other new SBU, viz. Oncotrust & Value India. The aim of each SBU is to attain leadership position in its respective markets and establish brand equity in respective therapeutic segment by implementing the concept of Customer Relationship Management (CRM) for better coverage and servicing of customers. The SBUs promote a portfolio of brands with a special focus on Orthopedicians, Cardiologists, Diabetologists, Physicians, Nephrologists, Pulmonologists, Surgeons, Dentists, ENT (Ear, Nose and Throat) specialists, Pediatricians and Gastro-enterologists.
Critical Care, a Super Speciality SBU of the company, is focused on Nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a complete range of pre-transplant & post-transplant therapies. The SBU has carved a niche in super-specialty segment and created a scientific image. The SBU is rightly poised for achieving clear leadership in the Nephrology &Transplantation segment.
Diabetology & Cardiovascular
Diacara is the highest contributing SBU of the company with dedicated marketing and sales infrastructure for Diabetes and Cardiovascular management. Diacar SBU is valued at Rs.460 million (ORG IMS Mar’07 MAT). The SBU promotes the brands to the target specialists viz. Endocrinologists, Diabetologists and Physicians in a fiercely competitive scenario and has achieved significant leadership position in Oral anti-diabetic segment.
Gastroenterology & Orthopedic
Procare SBU of the company endeavors to consolidate and strengthen its image in the field of chronic health care management with specific focus on pain and arthritis management, osteoporosis and gastrointestinal disorders. It promotes a portfolio of brands with special focus on Orthopedicians, Surgeons, Dentists, ENT specialist & Gastroenterologist apart from Consulting Physician and General Physician.
Growcare is the respiratory and pediatric business of Panacea Biotec. This business was carved out of the existing business of Panacea Biotec as part of the long term strategy to enter the high growth Respiratory Therapy. Growcare is a Rs.230 million business with total field strength of around 350 people and services more than 50,000 doctors across the country, in various specialties such as Chest Physicians, Consulting Physicians, Pediatricians and General Physicians. 26 different SKUs are marketed with presence in multiple Therapy areas.
Panacea Biotec has plans to foray into oncology segment to provide treatment for Cancer, viz, breast cancer, brain tumor, ovarian cancer, pancreatic cancer, prostrate cancer and colorectal cancer. ‘ Oncotrust’ would be the new Strategic Business Unit (SBU) with the total strength of around 50 sales specialists on oncology who would be responsible for marketing these drugs. The aim to register sales volumes of Rs. 150-200 million in oncology chemotherapy segment in the next three years. The Company feels that it would be able to launch novel drug delivery based anti-cancer drug in next 2-3 year period.
Value India Healthcare
Some of the brands include TwoWks, patented product to treat 1st & 2nd degree piles, Combipunch, a first time in India, DCGI approved formulation for allergic rhinitis and others.
VIH aims to provide a complete basket of products which a general practitioner needs on a daily basis. The Value range of antibiotics, ValueCef, ValueOrni & others, the pain range like Instanim, Nowaste Para, the respiratory range of KofZero, KoldZero are all steadily gaining the mindshare of the Doctor.
ValueIndia currently operates in Rest of Maharashtra, Madhya Pradesh & Chhattisgarh regions with plans for expansion to other states shortly.